By Fineline Cube 
Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo’s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China.
Financial Terms of the Agreement
Under the terms of the agreement, Velavigo will receive up to USD 440 million in total payments. This includes an upfront fee and future development, regulatory, and commercial milestone payments. Additionally, Velavigo will be entitled to tiered royalties based on sales performance.
Product Profile and Future Outlook
VBS-102 is a first-in-class bispecific antibody developed by Velavigo. The licensing agreement underscores the potential of this innovative therapeutic candidate and positions Ollin Biosciences to leverage its global footprint to bring this novel therapy to patients outside Greater China.-Fineline Info & Tech